vs

Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and Solo Brands, Inc. (SBDS). Click either name above to swap in a different company.

Solo Brands, Inc. is the larger business by last-quarter revenue ($94.0M vs $57.3M, roughly 1.6× RHYTHM PHARMACEUTICALS, INC.). RHYTHM PHARMACEUTICALS, INC. runs the higher net margin — -83.0% vs -88.4%, a 5.5% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -34.5%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 5.0%).

Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.

Conagra Brands, Inc. is an American consumer packaged goods holding company that makes and sells products under various brand names that are available in supermarkets, restaurants, and food service establishments. Based on its 2021 revenue, the company ranked 331st on the 2022 Fortune 500. Headquartered in Chicago, Illinois, Conagra was founded in Nebraska in 1919 and was originally called Nebraska Consolidated Mills.

RYTM vs SBDS — Head-to-Head

Bigger by revenue
SBDS
SBDS
1.6× larger
SBDS
$94.0M
$57.3M
RYTM
Growing faster (revenue YoY)
RYTM
RYTM
+71.4% gap
RYTM
36.9%
-34.5%
SBDS
Higher net margin
RYTM
RYTM
5.5% more per $
RYTM
-83.0%
-88.4%
SBDS
Faster 2-yr revenue CAGR
RYTM
RYTM
Annualised
RYTM
48.5%
5.0%
SBDS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RYTM
RYTM
SBDS
SBDS
Revenue
$57.3M
$94.0M
Net Profit
$-47.5M
$-83.2M
Gross Margin
91.6%
60.6%
Operating Margin
-82.2%
-81.7%
Net Margin
-83.0%
-88.4%
Revenue YoY
36.9%
-34.5%
Net Profit YoY
-9.6%
-42.9%
EPS (diluted)
$-0.73
$-45.73

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RYTM
RYTM
SBDS
SBDS
Q4 25
$57.3M
$94.0M
Q3 25
$51.3M
$53.0M
Q2 25
$48.5M
$92.3M
Q1 25
$32.7M
$77.3M
Q4 24
$41.8M
$143.5M
Q3 24
$33.3M
$94.1M
Q2 24
$29.1M
$131.6M
Q1 24
$26.0M
$85.3M
Net Profit
RYTM
RYTM
SBDS
SBDS
Q4 25
$-47.5M
$-83.2M
Q3 25
$-52.9M
$-22.9M
Q2 25
$-46.6M
$-20.8M
Q1 25
$-49.5M
$-18.6M
Q4 24
$-43.3M
$-58.2M
Q3 24
$-43.6M
$-111.5M
Q2 24
$-32.3M
$-4.0M
Q1 24
$-141.4M
$-6.5M
Gross Margin
RYTM
RYTM
SBDS
SBDS
Q4 25
91.6%
60.6%
Q3 25
89.3%
60.0%
Q2 25
88.6%
61.3%
Q1 25
88.8%
55.2%
Q4 24
90.9%
61.1%
Q3 24
88.5%
41.8%
Q2 24
89.9%
62.8%
Q1 24
89.2%
59.2%
Operating Margin
RYTM
RYTM
SBDS
SBDS
Q4 25
-82.2%
-81.7%
Q3 25
-102.6%
-30.5%
Q2 25
-93.4%
-10.7%
Q1 25
-143.7%
-13.8%
Q4 24
-98.6%
-38.5%
Q3 24
-132.0%
-122.5%
Q2 24
-139.2%
1.7%
Q1 24
-538.7%
-7.4%
Net Margin
RYTM
RYTM
SBDS
SBDS
Q4 25
-83.0%
-88.4%
Q3 25
-103.1%
-43.2%
Q2 25
-96.1%
-22.5%
Q1 25
-151.4%
-24.0%
Q4 24
-103.6%
-40.6%
Q3 24
-131.2%
-118.4%
Q2 24
-110.9%
-3.1%
Q1 24
-544.4%
-7.6%
EPS (diluted)
RYTM
RYTM
SBDS
SBDS
Q4 25
$-0.73
$-45.73
Q3 25
$-0.82
$-9.22
Q2 25
$-0.75
$-8.93
Q1 25
$-0.81
$-0.21
Q4 24
$-0.71
$-27.74
Q3 24
$-0.73
$-47.72
Q2 24
$-0.55
$-2.14
Q1 24
$-2.35
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RYTM
RYTM
SBDS
SBDS
Cash + ST InvestmentsLiquidity on hand
$388.9M
$20.0M
Total DebtLower is stronger
$242.1M
Stockholders' EquityBook value
$139.1M
$46.0M
Total Assets
$480.2M
$360.3M
Debt / EquityLower = less leverage
5.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RYTM
RYTM
SBDS
SBDS
Q4 25
$388.9M
$20.0M
Q3 25
$416.1M
$16.3M
Q2 25
$291.0M
$18.1M
Q1 25
$314.5M
$206.4M
Q4 24
$320.6M
$12.0M
Q3 24
$298.4M
$12.5M
Q2 24
$319.1M
$20.1M
Q1 24
$201.2M
$15.4M
Total Debt
RYTM
RYTM
SBDS
SBDS
Q4 25
$242.1M
Q3 25
$235.2M
Q2 25
$238.4M
Q1 25
$427.9M
Q4 24
$150.7M
Q3 24
$161.1M
Q2 24
$162.2M
Q1 24
$170.2M
Stockholders' Equity
RYTM
RYTM
SBDS
SBDS
Q4 25
$139.1M
$46.0M
Q3 25
$148.8M
$99.1M
Q2 25
$-11.9M
$113.2M
Q1 25
$18.9M
$121.7M
Q4 24
$21.7M
$133.7M
Q3 24
$11.2M
$168.0M
Q2 24
$39.3M
$236.7M
Q1 24
$61.6M
$238.5M
Total Assets
RYTM
RYTM
SBDS
SBDS
Q4 25
$480.2M
$360.3M
Q3 25
$506.9M
$431.0M
Q2 25
$372.7M
$459.7M
Q1 25
$386.7M
$692.4M
Q4 24
$392.3M
$495.1M
Q3 24
$363.6M
$553.2M
Q2 24
$381.8M
$642.0M
Q1 24
$258.7M
$648.3M
Debt / Equity
RYTM
RYTM
SBDS
SBDS
Q4 25
5.26×
Q3 25
2.37×
Q2 25
2.11×
Q1 25
3.52×
Q4 24
1.13×
Q3 24
0.96×
Q2 24
0.69×
Q1 24
0.71×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RYTM
RYTM
SBDS
SBDS
Operating Cash FlowLast quarter
$-25.4M
$6.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RYTM
RYTM
SBDS
SBDS
Q4 25
$-25.4M
$6.4M
Q3 25
$-26.6M
$11.2M
Q2 25
$-23.3M
$10.9M
Q1 25
$-40.4M
$-75.2M
Q4 24
$-18.8M
$13.0M
Q3 24
$-25.2M
$378.0K
Q2 24
$-29.1M
$15.7M
Q1 24
$-40.7M
$-18.5M
Free Cash Flow
RYTM
RYTM
SBDS
SBDS
Q4 25
Q3 25
Q2 25
Q1 25
$-78.4M
Q4 24
$9.0M
Q3 24
$-5.9M
Q2 24
$12.8M
Q1 24
$-20.9M
FCF Margin
RYTM
RYTM
SBDS
SBDS
Q4 25
Q3 25
Q2 25
Q1 25
-101.5%
Q4 24
6.3%
Q3 24
-6.3%
Q2 24
9.8%
Q1 24
-24.5%
Capex Intensity
RYTM
RYTM
SBDS
SBDS
Q4 25
Q3 25
Q2 25
Q1 25
4.2%
Q4 24
2.8%
Q3 24
6.7%
Q2 24
2.2%
Q1 24
2.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RYTM
RYTM

Segment breakdown not available.

SBDS
SBDS

Sales Channel Directly To Consumer$65.4M70%
Sales Channel Through Intermediary$28.6M30%

Related Comparisons